Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai to Offer 3 Rounds of Voluntary Retirement Program, to Cut 100 Jobs in March Next Year
October 26, 2018
- Xofluza Bags US Approval: Shionogi
October 26, 2018
- Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
October 25, 2018
- Swiss API Manufacturer Bachem Establishes Japanese Subsidiary
October 25, 2018
- GSK to Cover Cost of Rubella Testing and Vaccination for Employees
October 25, 2018
- AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
October 24, 2018
- Meiji Seika Pharma Files Safinamide for Parkinson’s Disease in Japan
October 24, 2018
- Regenerative Medicine Product Market to Reach 225 Billion Yen in 2030: Fuji Keizai
October 24, 2018
- Parexel CEO Sees Bright Future for Japan CRO Market
October 23, 2018
- DS-8201 Shows Overall Response Rate of 15.8% in Patients with Colorectal Cancer in Japan-US PI Study: Daiichi Sankyo
October 23, 2018
- Hisamitsu Begins Japan PII Study of Hyperhidrosis Treatment
October 23, 2018
- Eisai, MSD Begin Joint Information Provisioning for Lenvima in Japan
October 23, 2018
- Mitsubishi Tanabe Teams Up with Bioventure for Novel Antibody Drug Discovery Research in Autoimmune Diseases
October 23, 2018
- Mundipharma Shooting for Japan Sales of US$500 Million in 10 Years: CEO
October 22, 2018
- Daiichi Sankyo Begins 1st-in-Human Trial for AXL Inhibitor
October 22, 2018
- JCR’s Hunter Syndrome Drug Grabs FDA’s Orphan Status
October 22, 2018
- Eisai, Keio Univ. Identify Candidate Compound for Parkinson’s Disease Employing iPS Cells
October 22, 2018
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
- Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology
October 18, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…